Genetic testing company 23andMe, plagued by a data breach, dwindling sales, and failed forays into healthcare, filed for Chapter 11 bankruptcy, notifying customers to file potential claims by July 14 amid its restructuring and uncertain future.
MBZUAI unveils the Institute of Digital Public Health, harnessing AI foundation models and a data-driven approach to drive innovation across computational biology, precision medicine, infectious disease monitoring, and the UAE Genome Atlas for transformative public health solutions.
In a groundbreaking philanthropic move, Bill Gates announced that the Gates Foundation will spend its entire $200 billion endowment by 2045 on global initiatives like health, education, and development, marking one of the largest charitable donations in U.S. history.
OpenAI is in discussions with the FDA to explore leveraging AI, potentially through a project called cderGPT, to accelerate the drug approval process, with the FDA commissioner confirming the agency's first AI-assisted scientific review of a product.
ŌURA unveils groundbreaking AI-powered Meals and Glucose features, revolutionizing metabolic health tracking with AI-driven food recognition, nutrition analysis, personalized meal guidance, and seamless integration with Dexcom's Stelo for 24/7 glucose monitoring insights.
The Trump administration's deep cuts to science funding, including capping medical research grants and restricting diversity initiatives, threaten U.S. leadership in scientific research, potentially leading to layoffs and missed discoveries at agencies like the National Science Foundation.
Researchers have developed a groundbreaking method combining test-time augmentation and conformal prediction, enhancing AI model reliability by up to 30% for critical tasks like medical diagnosis, enabling more accurate and efficient decision-making in high-stakes scenarios.
Discover the remarkable advantages of walking in nature, where specific landscapes, sounds, and smells can profoundly enhance your physical and mental well-being, reducing stress, lowering blood pressure, and boosting immune function more effectively than urban environments.
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
In a groundbreaking development, researchers have harnessed the power of AI and machine learning to analyze patient data, enabling the prediction of Alzheimer's disease up to 7 years before symptoms manifest, with high cholesterol and osteoporosis emerging as key predictors.